跳转至内容
Merck
CN

B9156

Butorphanol (+)-tartrate salt

≥99%

别名:

L-N-Cyclobutylmethyl-3,14-dihydroxymorphinan (+)-tartrate salt

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C21H29NO2 · C4H6O6
化学文摘社编号:
58786-99-5
分子量:
477.55
NACRES:
NA.77
PubChem Substance ID:
24892126
UNSPSC Code:
12352200
EC Number:
261-443-5
MDL number:
MFCD00214257

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Butorphanol (+)-tartrate salt, ≥99%

InChI key

GMTYREVWZXJPLF-BTVKVFNOSA-N

InChI

1S/C21H29NO2.C4H6O6/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15;5-1(3(7)8)2(6)4(9)10/h6-7,13,15,19,23-24H,1-5,8-12,14H2;1-2,5-6H,(H,7,8)(H,9,10)/t19-,20+,21-;1-,2-/m11/s1

SMILES string

O[C@H]([C@@H](O)C(O)=O)C(O)=O.Oc1ccc2C[C@H]3N(CC[C@@]4(CCCC[C@@]34O)c2c1)CC5CCC5

assay

≥99%

form

powder

drug control

USDEA Schedule IV; psychotrope (France); regulated under CDSA - not available from Sigma-Aldrich Canada

originator

Bristol-Myers Squibb

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... OPRK1(4986), OPRM1(4988)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

κ/μ opioid receptor agonist.

Features and Benefits

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H361

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLCN8441
SLCF7384
SLBR8990V
SLBR0761V
SLBM0691V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

J A Vivian et al.
The Journal of pharmacology and experimental therapeutics, 290(1), 259-265 (1999-06-25)
Butorphanol and nalbuphine have substantial affinity for mu and kappa-opioid receptor sites, yet their behavioral effects in monkeys are largely consistent with a mu receptor mechanism of action. Using ethylketocyclazocine (EKC) discrimination and diuresis assays in rhesus monkeys (Macaca mulatta)
J C Chen et al.
Life sciences, 52(4), 389-396 (1993-01-01)
The ability of morphine, fentanyl, butorphanol, nalbuphine, and dezocine to compete with radiolabeled ligands for binding at the mu1, mu2, kappa1, and delta opioid receptors and the sigma receptor was characterized. In the absence of sodium, the potency of opioid

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持